{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:01:59Z","timestamp":1785340919890,"version":"3.55.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Individuals with opioid use disorder and substance use disorder have lower cervical cancer screening rates than the general population. Human papillomavirus (HPV) self-collection testing provides opportunities to expand screening access to previously unreached patient populations.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To assess the feasibility and uptake of incorporating HPV self-collection testing for cervical cancer screening into routine care for patients with opioid use disorder and substance use disorder, and to track the rates of high-risk HPV and guideline concordant follow-up care in this population.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective cohort study was conducted from June 24, 2024, through December 31, 2025, at We Care Daily Clinics, a federally certified opioid treatment program (OTP) and American Indian Health Facility in Auburn, Washington. Eligible patients were 25 years or older, had a cervix, and were either overdue for cervical cancer screening or unsure of their last screening.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Screening using self-collection kits was offered during the patient\u2019s annual wellness visit, and self-collection occurred privately in the clinic restroom. Samples were analyzed for 14 high-risk HPV types at a laboratory. Screened patients with HPV-positive results received education and recommendations for guideline-concordant care. OTP staff facilitated patient referrals to local clinicians for gynecologic services, and follow-up was tracked.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were the rates of HPV self-collection testing uptake, HPV positivity, and successful linkage to follow-up care.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 194 patients (median [range] age, 41 [25-65] years) were evaluated. Of 174 patients (89.7%) eligible for cervical cancer screening, 158 (90.8%) completed HPV self-collection testing. There were 0 unsatisfactory test results, and 128 patients (81.0%) had HPV-negative results, 7 (4.4%) had HPV-16\u2013 or HPV-18\u2013positive results, and 23 (14.6%) had positive results for other high-risk HPV types (non\u2013HPV-16 or HPV-18 types only). Of the 30 patients with HPV-positive test results, 2 (6.7%) were lost to follow-up and 12 (40.0%) completed follow-up to date, which often required multiple coordination attempts by clinicians. The remaining 16 of 30 patients (53.3%) are currently actively engaged in various stages of referral and scheduling.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, incorporation of cervical cancer screening into an OTP using HPV self-collection testing was feasible with high patient eligibility and uptake.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.25993","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:30:22Z","timestamp":1785339022000},"page":"e2625993","source":"Crossref","is-referenced-by-count":0,"title":["Cervical Cancer Screening With Human Papillomavirus Self-Collection Testing in an Opioid Treatment Program"],"prefix":"10.1001","volume":"9","author":[{"given":"Elizabeth M.","family":"Swisher","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Davis","sequence":"additional","affiliation":[{"name":"We Care Daily Clinics, Auburn, Washington"},{"name":"Department of Family Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Rubin-Saika","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enna","family":"Manhardt","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata R.","family":"Urban","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Cherne","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"School of Public Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"Winer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Washington, Seattle"},{"name":"School of Public Health, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hutch","sequence":"additional","affiliation":[{"name":"We Care Daily Clinics, Auburn, Washington"},{"name":"Department of Family Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"3","key":"zoi260717r1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.jncc.2024.11.006","article-title":"Global burden of cervical cancer: current estimates, temporal trend and future projections based on the GLOBOCAN 2022.","volume":"5","author":"Wu","year":"2025","journal-title":"J Natl Cancer Cent"},{"issue":"9","key":"zoi260717r2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35833","article-title":"Annual Report to the Nation on the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemic.","volume":"131","author":"Sherman","year":"2025","journal-title":"Cancer"},{"key":"zoi260717r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101243","article-title":"Two decades of the HPV vaccine: its promise, progress, prospects, projections, and posterity.","volume":"51","author":"Zeitouni","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"zoi260717r4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ypmed.2019.04.010","article-title":"Trends in cervical cancer incidence rates by age, race\/ethnicity, histological subtype, and stage at diagnosis in the United States.","volume":"123","author":"Islami","year":"2019","journal-title":"Prev Med"},{"issue":"3","key":"zoi260717r5","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1002\/cam4.5226","article-title":"Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings.","volume":"12","author":"Chao","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"zoi260717r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.43582","article-title":"Assessment of US Preventive Services Task Force guideline-concordant cervical cancer screening rates and reasons for underscreening by age, race and ethnicity, sexual orientation, rurality, and insurance, 2005 to 2019.","volume":"5","author":"Suk","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi260717r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106596","article-title":"Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities.","volume":"151","author":"Wentzensen","year":"2021","journal-title":"Prev Med"},{"issue":"7","key":"zoi260717r8","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/1055-9965.EPI-23-0114","article-title":"Updated review of major cancer risk factors and screening test use in the United States, with a focus on changes during the COVID-19 pandemic.","volume":"32","author":"Star","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"zoi260717r9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3322\/caac.21628","article-title":"Cervical cancer screening for individuals at average risk: 2020 Guideline Update from the American Cancer Society.","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"zoi260717r10","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2018.10400","article-title":"Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"320","author":"Melnikow","year":"2018","journal-title":"JAMA"},{"issue":"11","key":"zoi260717r11","doi-asserted-by":"publisher","first-page":"e886","DOI":"10.1016\/S2468-2667(24)00218-4","article-title":"Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden.","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Public Health"},{"key":"zoi260717r12","doi-asserted-by":"publisher","first-page":"k4823","DOI":"10.1136\/bmj.k4823","article-title":"Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.","volume":"363","author":"Arbyn","year":"2018","journal-title":"BMJ"},{"issue":"11","key":"zoi260717r13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.44343","article-title":"Effect of patient characteristics on uptake of screening using a mailed human papillomavirus self-sampling kit: a secondary analysis of a randomized clinical trial.","volume":"5","author":"Winer","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"20","key":"zoi260717r14","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1001\/jama.2023.21471","article-title":"Strategies to increase cervical cancer screening with mailed human papillomavirus self-sampling kits: a randomized clinical trial.","volume":"330","author":"Winer","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"zoi260717r15","first-page":"597","article-title":"Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: focused literature review.","volume":"63","author":"Madzima","year":"2017","journal-title":"Can Fam Physician"},{"issue":"1","key":"zoi260717r16","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1186\/s12889-021-11554-6","article-title":"Self-collection for HPV-based cervical screening: a qualitative evidence meta-synthesis.","volume":"21","author":"Camara","year":"2021","journal-title":"BMC Public Health"},{"issue":"5","key":"zoi260717r17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s10552-021-01406-4","article-title":"Acceptability of a multicomponent, community-based, HPV self-test intervention among Jamaican women.","volume":"32","author":"Julian McFarlane","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"6","key":"zoi260717r18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ijc.35222","article-title":"Acceptability and validity of HPV self-sampling for cervical cancer screening among women living in different ecological settings in India.","volume":"156","author":"Mishra","year":"2025","journal-title":"Int J Cancer"},{"issue":"1565","key":"zoi260717r19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.26635\/6965.5856","article-title":"Feasibility and acceptability of telehealth and contactless delivery of human papillomavirus (HPV) self-testing for cervical screening with Maori and Pacific women in a COVID-19 outbreak in Aotearoa New Zealand.","volume":"135","author":"Bartholomew","year":"2022","journal-title":"N Z Med J"},{"issue":"1","key":"zoi260717r20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/OLQ.0000000000000681","article-title":"Mailed human papillomavirus self-collection with Papanicolaou test referral for infrequently screened women in the United States.","volume":"45","author":"Smith","year":"2018","journal-title":"Sex Transm Dis"},{"key":"zoi260717r21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2019.01.037","article-title":"Strategies used by people who inject drugs to avoid stigma in healthcare settings.","volume":"198","author":"Biancarelli","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"zoi260717r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104382","article-title":"Vaccination coverage among people who inject drugs: a systematic review.","volume":"127","author":"Price","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi260717r23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12954-020-00395-y","article-title":"Providing reproductive health services for women who inject drugs: a pilot program.","volume":"17","author":"Owens","year":"2020","journal-title":"Harm Reduct J"},{"key":"zoi260717r24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.socscimed.2019.01.022","article-title":"A qualitative study on intersectional stigma and sexual health among women on opioid substitution treatment in England: implications for research, policy and practice.","volume":"222","author":"Medina-Perucha","year":"2019","journal-title":"Soc Sci Med"},{"issue":"11","key":"zoi260717r25","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/ijgc-2024-005784","article-title":"FDA approves the first HPV self-collection solutions.","volume":"34","author":"Bilir","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"zoi260717r27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/LGT.0000000000000788","article-title":"2019 ASCCP Risk-Based Management Consensus Guidelines: updates through 2023.","volume":"28","author":"Perkins","year":"2024","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"zoi260717r28","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/08897077.2021.2010257","article-title":"Cervical cancer screening, abnormal results, and follow-up in women with substance use-related diagnoses.","volume":"43","author":"Eastment","year":"2022","journal-title":"Subst Abus"},{"issue":"1","key":"zoi260717r29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12889-023-15236-3","article-title":"Participation in screening for breast and cervical cancer among women with current or previous drug use: a survey study.","volume":"23","author":"Garpenhag","year":"2023","journal-title":"BMC Public Health"},{"issue":"12","key":"zoi260717r30","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/pon.5815","article-title":"Predictors of cancer screening among Black and White Maryland Medicaid enrollees with serious mental illness.","volume":"30","author":"Murphy","year":"2021","journal-title":"Psychooncology"},{"issue":"8","key":"zoi260717r31","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.3390\/ijerph19084555","article-title":"Cancer screening among rural people who use drugs: colliding risks and barriers.","volume":"19","author":"Jenkins","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"zoi260717r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2024.100218","article-title":"Colorectal cancer screening among individuals with a substance use disorder: a retrospective cohort study.","volume":"3","author":"Sonoda","year":"2024","journal-title":"AJPM Focus"},{"key":"zoi260717r33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.drugpo.2018.04.004","article-title":"Stigma at every turn: health services experiences among people who inject drugs.","volume":"57","author":"Paquette","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi260717r34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1081\/ADA-200056772","article-title":"Interpersonal discrimination and the health of illicit drug users.","volume":"31","author":"Young","year":"2005","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"11","key":"zoi260717r35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002969","article-title":"Stigma as a fundamental hindrance to the United States opioid overdose crisis response.","volume":"16","author":"Tsai","year":"2019","journal-title":"PLoS Med"},{"issue":"1","key":"zoi260717r36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12954-024-01070-2","article-title":"Fentanyl harm reduction strategies among Latinx communities in the United States: a scoping review.","volume":"21","author":"Luna","year":"2024","journal-title":"Harm Reduct J"},{"issue":"2","key":"zoi260717r37","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s40429-021-00373-9","article-title":"New approaches in drug dependence: opioids.","volume":"8","author":"Mielau","year":"2021","journal-title":"Curr Addict Rep"},{"issue":"12","key":"zoi260717r38","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1007\/s11606-021-06904-4","article-title":"Integrating harm reduction into outpatient opioid use disorder treatment settings: harm reduction in outpatient addiction treatment.","volume":"36","author":"Taylor","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"14","key":"zoi260717r39","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1001\/jama.286.14.1715","article-title":"Integrating primary medical care with addiction treatment: a randomized controlled trial.","volume":"286","author":"Weisner","year":"2001","journal-title":"JAMA"},{"issue":"8","key":"zoi260717r40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28627","article-title":"Integrating opioid use disorder treatment into primary care settings.","volume":"6","author":"Austin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi260717r26","unstructured":"Inside knowledge about cervical cancer. Centers for Disease Control and Prevention. Revised January 2019. Accessed June 23, 2026. https:\/\/www.cdc.gov\/cancer\/cervical\/pdf\/cervical_facts.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2852221\/swisher_2026_oi_260717_1784730452.58466.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:30:23Z","timestamp":1785339023000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2852221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.25993","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}